Project Grant 2538015
Award Date 7/1/26
Completion Date 6/30/27
Dollars Obligated $305K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Watertown, MA 02472, USA
Similar Awards
- Federal Project Grant Summary Endura Therapeutics Inc. received a $303,445 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) on May 15, 2025, with completion targeted for January 31, 2026. The award funds development of a next-generation sequencing-based platform designed to discover and screen small molecule drugs that target RNA. The primary deliverables include establishing...
- Federal Grant Award Summary Neucore Bio, Inc. received a $304,951 Phase I Small Business Technology Transfer (STTR) award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) on June 15, 2025, with a completion date of May 31, 2026. The award funds development of fibroblast-derived engineered extracellular vesicles (EEVs) as nucleic acid therapeutic delivery systems for peripheral nervous system genetic disorders, with an initial focus...
- Award Summary Orion Therapeutics Inc. received a $1.25M Small Business Technology Transfer (STTR) Phase II Cooperative Agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084), awarded September 15, 2025, with completion targeted for August 31, 2027. The project focuses on developing and advancing a multifunctional lipid nanoparticle (LNP) delivery platform designed to enable safe and targeted delivery of RNA therapeutics to specific...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...
- Federal Project Grant Award Summary The National Science Foundation's Directorate for Technology, Innovation, and Partnerships (TIP) awarded $305,000 to a small business under the SBIR Phase I program (CFDA 47.084) to develop a novel gene therapy platform that overcomes the cargo size limitations of adeno-associated virus (AAV) delivery systems. The project, initiated July 1, 2026 with completion targeted for December 31, 2027, focuses on designing and validating a scalable platform to deliver...
- Federal Grant Award Summary Nitro Biosciences Inc. received a $304,438 Small Business Technology Transfer (STTR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) effective October 1, 2025, with a completion date of September 30, 2026. The award supports development of an innovative vaccine platform utilizing engineered antigens containing chemically modified amino acids to overcome immune imprinting—a critical...
- This SBIR Phase I project awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program seeks to develop a new class of gene therapies that can be delivered more safely, cost-effectively, and at scale for a wide range of serious genetic disorders. The project leverages short oligonucleotides conjugated with small molecules to induce proximity of endogenous epigenetic machinery to disease-relevant genes in a precise and reversible...
- Federal Grant Award Summary Immuno Nano Med, Inc. received a $305,000 Small Business Technology Transfer (STTR) Phase I award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships program (CFDA 47.084), effective October 1, 2025, with completion targeted for September 30, 2026. The award supports development and feasibility demonstration of a novel room-temperature-stable, dry-powder inhalable influenza vaccine utilizing a scalable manufacturing process....
- The National Science Foundation awarded Diant Pharma Inc. a $256,000 Project Grant under the Engineering (47.041) federal grant program. The grant will support development of an advanced continuous manufacturing system for nucleic acid lipid nanoparticles to improve supply chains for therapeutics and vaccines. Specifically, the small business innovation research Phase I project aims to create a compact, end-to-end manufacturing platform that follows current good manufacturing practices. This...
- Federal Grant Award Summary Autonomous Therapeutics Inc. received a $1.004 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 10, 2025, with completion targeted for August 31, 2028. The company is developing AT191, a first-in-class inhaled encrypted RNA (EncRNA) therapeutic designed to provide variant-proof efficacy...